PLAQUE REDUCTION WITH CONCURRENT REDUCTION/PREVENTION OF GINGIVITIS
This article was originally published in The Rose Sheet
PLAQUE REDUCTION WITH CONCURRENT REDUCTION/PREVENTION OF GINGIVITIS are the most appropriate endpoints for demonstrating effectiveness of OTC plaque products, according to a draft "points to consider" document prepared by members of FDA's OTC Plaque Subcommittee and discussed at a Dec. 7 meeting. Under a subheading on clinical trials contained in a section on evaluating effectiveness, the document states that "the effectiveness of an OTC antiplaque or antiplaque-related ingredient can best be demonstrated by the evidence of clinically significant endpoints, specifically, a reduction of dental plaque associated with a concurrent reduction and/or prevention of gingivitis."
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
The National Advertising Division concludes that by claiming the Schick Intuition Plus razor "lathers, shaves and moisturizes in one easy step," Energizer Personal Care is implying a long-term post-shave benefit comparable to that awarded by leave-on moisturizer, which is not supported by the company's evidence